Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TCF4 | P15884 | 1/20 | 1.00 |
| ▸ | CTNNB1 | P35222 | 1/20 | 1.00 |
| ▸ | HPGD | P15428 | 3/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.58 |
| ▸ | MAPT | P10636 | 2/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | ESR1 | P03372 | 1/20 | 0.58 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.58 |
| ▸ | NQO2 | P16083 | 2/20 | 0.53 |
| ▸ | CA1 | P00915 | 4/20 | 0.52 |
| ▸ | CA2 | P00918 | 4/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9771872 | 1.00 | TCF4 (1.00) | TCF4CTNNB1HPGDALDH1A1KDM4E | |
| SCHEMBL9771867 | 1.00 | TCF4 (1.00) | TCF4CTNNB1HPGDALDH1A1KDM4E | |
| SCHEMBL20781167 | 0.93 | TCF4 (0.87) | TCF4CTNNB1HPGDALDH1A1KDM4E | |
| SCHEMBL1849661 | 0.82 | TCF4 (0.69) | TCF4CTNNB1HPGDALDH1A1KDM4E | |
| SCHEMBL1849660 | 0.82 | TCF4 (0.69) | TCF4CTNNB1HPGDALDH1A1KDM4E | |
| SCHEMBL11418451 | 0.81 | TCF4 (0.69) | TCF4CTNNB1HPGDALDH1A1KDM4E | |
| SCHEMBL11418449 | 0.81 | TCF4 (0.69) | TCF4CTNNB1HPGDALDH1A1KDM4E | |
| SCHEMBL9594879 | 0.81 | TCF4 (0.68) | TCF4CTNNB1HPGDALDH1A1KDM4E | |
| SCHEMBL1850553 | 0.80 | TCF4 (0.66) | TCF4CTNNB1HPGDALDH1A1KDM4E | |
| SCHEMBL1850554 | 0.80 | TCF4 (0.66) | TCF4CTNNB1HPGDALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230293565-A1 | USE OF WNT/BETA-CATENIN PATHWAY INHIBITORS TO BLOCK REPLICATION OF SARS-COV-2 AND OTHER PATHOGENIC VIRUSES | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2023-09-21 | — | — | US | claimed |
| CN-116249520-A | Blocking replication of SARS-COV-2 and other pathogenic viruses using WNT/beta-catenin pathway inhibitors | 阿尔伯塔大学理事会 | 2023-06-09 | — | — | CN | claimed |
| EP-4188378-A1 | USE OF WNT/BETA-CATENIN PATHWAY INHIBITORS TO BLOCK REPLICATION OF SARS-COV-2 AND OTHER PATHOGENIC VIRUSES | The Governors of the University of Alberta (CA) | 2023-06-07 | — | — | EP | claimed |
| EP-3675880-B1 | TARGETED EPIGENETIC THERAPY FOR INHERITED AORTIC ANEURYSM CONDITION | UNIV JOHNS HOPKINS (US) | 2023-06-07 | — | — | EP | claimed |
| US-11273148-B2 | Targeted epigenetic therapy for inherited aortic aneurysm condition | THE JOHNS HOPKINS UNIVERSITY (US) | 2022-03-15 | — | — | US | claimed |
| WO-2022020967-A1 | USE OF WNT/BETA-CATENIN PATHWAY INHIBITORS TO BLOCK REPLICATION OF SARS-COV-2 AND OTHER PATHOGENIC VIRUSES | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2022-02-03 | — | — | WO | claimed |
| WO-2026106912-A1 | RAS INHIBITORS | Revolution Medicines, Inc. (US) | 2026-05-21 | — | — | WO | disclosed |
| EP-4743080-A2 | METHODS OF TREATING A RAS RELATED DISEASE OR DISORDER | Revolution Medicines, Inc. (US) | 2026-05-20 | — | — | EP | disclosed |
| WO-2026090127-A1 | METHODS OF TREATING A RAS PROTEIN-RELATED DISEASE OR DISORDER | Revolution Medicines, Inc. (US) | 2026-04-30 | — | — | WO | disclosed |
| WO-2026090116-A2 | RAS INHIBITORS | Revolution Medicines, Inc. (US) | 2026-04-30 | — | — | WO | disclosed |
| WO-2026090245-A1 | USE OF RAS INHIBITORS FOR TREATING CANCER | Revolution Medicines, Inc. (US) | 2026-04-30 | — | — | WO | disclosed |
| US-20260108528-A1 | METHODS OF TREATING A RAS PROTEIN-RELATED DISEASE OR DISORDER | REVOLUTION MEDICINES INC (US) | 2026-04-23 | — | — | US | disclosed |
| EP-4704850-A1 | COMBINATION THERAPY FOR A RAS RELATED DISEASE OR DISORDER | Revolution Medicines, Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| WO-2019046791-A9 | TARGETED EPIGENETIC THERAPY FOR INHERITED AORTIC ANEURYSM CONDITION | THE JOHNS HOPKINS UNIVERSITY (US) | 2022-07-07 | — | — | WO | disclosed |
| EP-4013466-A1 | METHOD FOR IN VITRO PRODUCTION OF HYALINE CARTILAGE TISSUE | Vanarix SA (CH) | 2022-06-22 | — | — | EP | disclosed |
| CN-114555783-A | Method for producing hyaline cartilage tissue in vitro | 瓦纳里克斯股份公司 | 2022-05-27 | — | — | CN | disclosed |
| EP-3982922-A1 | DISSACHARIDE FORMULATIONS FOR CONTROLLED DRUG RELEASE | Technical University of Denmark (DK) | 2022-04-20 | — | — | EP | disclosed |
| US-11273148-B2 | Targeted epigenetic therapy for inherited aortic aneurysm condition | THE JOHNS HOPKINS UNIVERSITY (US) | 2022-03-15 | — | — | US | disclosed |
| WO-2022020967-A1 | USE OF WNT/BETA-CATENIN PATHWAY INHIBITORS TO BLOCK REPLICATION OF SARS-COV-2 AND OTHER PATHOGENIC VIRUSES | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2022-02-03 | — | — | WO | disclosed |
| US-20200253932-A1 | TARGETED EPIGENETIC THERAPY FOR INHERITED AORTIC ANEURYSM CONDITION | THE JOHNS HOPKINS UNIVERSITY | 2020-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11273148-B2 | Targeted epigenetic therapy for inherited aortic aneurysm condition | HDAC1, HDAC11, HDAC7 | TCF4 376/4885CTNNB1 784/4885HPGD 3197/4885 |
| US-20200253932-A1 | TARGETED EPIGENETIC THERAPY FOR INHERITED AORTIC ANEURYSM CONDITION | HDAC1, HDAC11, HDAC7 | TCF4 376/4885CTNNB1 784/4885HPGD 3197/4885 |
| US-20260108528-A1 | METHODS OF TREATING A RAS PROTEIN-RELATED DISEASE OR DISORDER | KRAS, NRAS, RAB1A | TCF4 4206/4885CTNNB1 653/4885HPGD 2067/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.